Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof.
Type:
Grant
Filed:
June 5, 2017
Date of Patent:
February 4, 2020
Assignee:
ALDERBIO HOLDINGS LLC
Inventors:
Andrew Lawrence Feldhaus, Leon Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katie Olson Anderson, Ethan Wayne Ojala, Pei Fan, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Jeffrey T. L. Smith, John Latham
Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Embodiments of this invention relate to the binding fragments of antibodies described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof.
Type:
Grant
Filed:
August 13, 2018
Date of Patent:
January 28, 2020
Assignee:
ALDERBIO HOLDINGS LLC
Inventors:
Andrew Lawrence Feldhaus, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katie Olson Anderson, Ethan Wayne Ojala, Pei Fan, Charlie Karasek, Jenny A. Mulligan, Danielle Marie Mitchell, Patricia Dianne McNeill, Michelle L. Scalley-Kim, Erica Stewart, Jeffrey T. L. Smith, John Latham
Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations. The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.
Abstract: There are many reports of diseases caused by overeating, satiation, and an unbalanced diet, and various therapeutic methods and therapeutic drugs are proposed for said diseases. There have not been many proposals, for prevention of these diseases, of methods by which what is eaten is not readily absorbed in vivo. The present invention involves inoculating female birds with a digestive enzyme as an antigen, said digestive enzyme being present in vivo. As a result of inhibiting the activity of the digestive enzyme by using an antibody which has been produced in vivo in the birds, the present invention inhibits decomposition of proteins, lipids, and carbohydrates and reduces in vivo absorption. This type of antibody can be obtained from an egg laid by a female bird which has received the antigen, and furthermore the egg itself includes the antibody. Consequently, a food product that contains, as an ingredient thereof, eggs having this type of antibody is low in proteins, lipids, and carbohydrates.
Abstract: Compositions containing multivalent and monovalent multispecific complexes having scaffolds such as antibodies that support such binding functionalities are described. The use of and methods of compositions containing multivalent and monovalent multispecific complexes having scaffolds, such as antibodies, that support such binding functionalities are also described.
Type:
Grant
Filed:
March 14, 2017
Date of Patent:
January 7, 2020
Assignee:
Zygenia, Inc.
Inventors:
Viktor Roschke, David Lafleur, David M. Hilbert, Peter Kiener
Abstract: According to this invention, the following are provided: a pharmaceutical composition for treating and/or preventing esophageal stenosis, comprising an HGF protein as an active ingredient (wherein the HGF protein may be a polypeptide that is any one of the following: (a) a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 2; (b) a polypeptide comprising an amino acid sequence shown in SEQ ID NO: 2 in which one to several amino acids are deleted, substituted, or added; or (c) a polypeptide comprising an amino acid sequence having at least 90% identity with the amino acid sequence shown in SEQ ID NO: 2; and a stent comprising the pharmaceutical composition.
Abstract: Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.
Type:
Grant
Filed:
March 6, 2017
Date of Patent:
December 10, 2019
Assignees:
SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, UNIVERSITY OF ULSAN, KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, PHAROSGEN
Inventors:
Youngro Byun, In San Kim, Ahmed Al-Hilal Taslim, Sang-Yoon Kim, Ye Ji Jang
Abstract: Provided herein are compositions and methods for the treatment of tendinopathies, such as tenosynovitis, tendinosis or tendinitis, including Achilles tendinopathy, patellar tendinopathy, lateral epicondylitis or “tennis elbow,” medial epicondylitis or “golfer's elbow,” plantar fasciitis, and rotator cuff tendinopathy, and in particular to methods for the treatment of tendinopathies by administering compositions comprising platelet-derived growth factor (PDGF).
Type:
Grant
Filed:
March 31, 2017
Date of Patent:
December 3, 2019
Assignee:
BIOMIMETIC THERAPEUTICS, LLC
Inventors:
Hans K. Kestler, Vivek Shah, Dean James Rager-Aguiar
Abstract: This invention relates to mutant polypeptides comprising the IGF2 binding domain of the Insulin-like Growth Factor 2 Receptor (IGF2R) with residue P1597 is substituted for a different residue, for example H or K. Other residues which may be mutated include S1543, E1544, K1545, G1546, L1547, Q1569, S1602, G1603 and/or K1631. These IGF2 binding domains display dramatically increased binding affinity for IGF2 compared to both the wild-type and previously identified mutants and may be useful for example in cancer therapy.
Type:
Grant
Filed:
August 8, 2016
Date of Patent:
December 3, 2019
Assignee:
Oxford University Innovation
Inventors:
Matthew Philip Crump, Andrew Bassim Hassan
Abstract: Provided are a platelet-derived growth factor B derivative, the encoding nucleic acid molecule thereof, and a vector and host cell having the nucleic acid molecule. Also provided are a preparation method for the mutant, and the use of the mutant in preparing medications for promoting cell division, cell proliferation, wound healing, skin regeneration, bone and tooth defect regeneration, and joint repair.
Type:
Grant
Filed:
July 16, 2015
Date of Patent:
October 22, 2019
Assignee:
Institute of Biotechnology Academy of Military Medical Sciences P.L.A. China
Inventors:
Wei Chen, Xiaopeng Zhang, Changming Yu, Ling Fu, Mengmeng Dai, Jun Zhang, Junjie Xu, Lihua Hou, Jianmin Li
Abstract: This application discloses ophthalmic formulations and methods for treating and preventing corneal haze and scarring with an hepatocyte growth factor (HGF) agent.
Type:
Grant
Filed:
September 9, 2016
Date of Patent:
October 22, 2019
Assignee:
The Schepens Eye Research Institute, Inc.
Abstract: The present invention provides antibodies that bind to ANGPTL8 and methods of using the same. According to certain embodiments, the invention includes methods of using anti-ANGPTL8 antibodies that bind human ANGPTL8 with high affinity to treat obesity, reduce body fat, reduce body weight, increase energy expenditure, and increase HDL-C, in a subject.
Type:
Grant
Filed:
November 17, 2017
Date of Patent:
October 15, 2019
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Viktoria Gusarova, Jesper Gromada, Andrew J. Murphy
Abstract: A method for treating wrinkle or aging on a skin of a subject includes applying to the skin a composition that includes a green fluorescent protein-human epidermal growth factor fusion protein as an effective component. Since the fusion protein has an excellent anti-oxidation activity and a high skin cell proliferation effect, it can be advantageously used as a raw material of functional cosmetics having excellent skin regeneration effect like improvement of skin wrinkles and skin whitening.
Type:
Grant
Filed:
January 25, 2017
Date of Patent:
October 15, 2019
Assignees:
NEXGEN BIOTECHNOLOGIES, INC.
Inventors:
Sun Kyo Lee, Seong Ran Lee, Han Bong Ryu, Tae Hyun Kim, Tae Won Choi, Hyeong Il Kwon
Abstract: Disclosed are proteins derived from the HGF/SF which are able to induce activation of the tyrosine kinase receptor MET and their uses, in particular to promote tissue regeneration. Further disclosed are nucleic acid molecules coding such protein, expression vectors containing such nucleic acid molecule, host cells containing such expression vectors, and related compositions.
Type:
Grant
Filed:
January 21, 2016
Date of Patent:
October 8, 2019
Assignees:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT PASTEUR DE LILLE, UNIVERSITA' DEGLI STUDI DI PAVIA, UNIVERSITÉ DE LILLE
Inventors:
Jerome Vicogne, Oleg Melnyk, Nathalie Ollivier, Eric Adriaenssens, Berenice Leclercq, Claire Simonneau, Giovanni De Nola, Ermanno Gherardi, Hugo De Jonge
Abstract: A fusion polypeptide comprising (A)x-M-(A?)y, wherein A and A? are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A? may be each be an antibody or fragment derived from an antibody specific for a target receptor, such as the same or different scFv fragments, and/or a ligand or ligand fragment or derivative capable of binding the target protein, M is a multimerizing component, and X and Y are independently a number between 1-10.
Type:
Grant
Filed:
November 9, 2017
Date of Patent:
October 1, 2019
Assignee:
REGENERON PHARMACEUTICALS, INC.
Inventors:
James P. Fandl, Gang Chen, Nicholas J. Papadopoulos, Thomas H. Aldrich
Abstract: The present invention relates to a novel protein secretion factor, a vector including a nucleic acid sequence encoding the protein secretion factor, and a transformed cell into which the vector is introduced. The invention also relates to a method of producing a target protein using the transformed cell including the vector.
Type:
Grant
Filed:
April 30, 2015
Date of Patent:
September 10, 2019
Assignee:
LG CHEM, LTD.
Inventors:
Seung Hae Kim, Yeon Chul Kim, Saem Jung
Abstract: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.
Type:
Grant
Filed:
September 13, 2017
Date of Patent:
September 3, 2019
Assignee:
Salk Institute for Biological Studies
Inventors:
Johan W. Jonker, Michael Downes, Ronald M. Evans, Jae Myoung Suh
Abstract: Fusion proteins comprising cytokines, particularly insulin-like growth factor-1 (IGF-1) and variants thereof, epidermal growth factor (EGF), and other ligands to the EGF receptor, are provided. The fusion proteins further comprise SEQ ID NO:1 or other segments having lysine, glutamic acid, or aspartic acid residues. Uses for the fusion proteins are also provided.
Abstract: Methods are disclosed that are based on the finding that serum and plasma levels of eotaxin, MIP1?, and CRP act as important biomarkers that are useful for determining the feasibility in instigating immunotherapeutic treatment of cancer when immunizing with the GV1001 peptide (EARPALLTSRLRFIPK; derived from human telomerase protein), optionally when combined with state of the art combination treatment with Gemcitabine and Capecitabine. In particular, the present invention provides methods for determining whether patients should be treated GV1001 and for determining whether instigated treatment should be continued.
Abstract: The present invention relates to the development of stable mutants of FGF-1 and FGF-2. In particular, it relates to novel engineered FGF-1 and FGF-2 polypeptides as well as polynucleotides, DNA constructs, and vectors encoding such polypeptides. In another aspect, pharmaceutical compositions and hydrogels including the disclosed polypeptides, polynucleotides, DNA constructs, and vectors are provided. In a still further aspect, methods of treating conditions using the compositions disclosed herein are provided.
Type:
Grant
Filed:
March 30, 2017
Date of Patent:
August 20, 2019
Assignee:
The Board of Trustees of the University of Arkansas
Inventors:
Suresh Kumar Thallapuranam, David A. Zaharoff, Srinivas Jayanthi, Bhanuprasanth Koppolu, Rebecca Kerr, Kartik Balachandran, David S. McNabb